Anti-inflammatory activity and secondary metabolite profiling of Eucalyptus camaldulensis (Myrtaceae)
Kolade O. Faloye , Oluwapelumi E. Ekundayo , Silas A. Oke , Augusta U. Nwogu , Stephen A. Adesida , Esther A. Olanudun , Boluwaji O. Makinde , Godwin Anyim , Maryam O. Bakare , Samson O. Famuyiwa
Exploration of Drug Science ›› 2026, Vol. 4 ›› Issue (1) : 1008163
Aim: This study investigated the anti-inflammatory effect of the extract and fractions of Eucalyptus camaldulensis and also profiled the secondary metabolites of its most active fraction.
Methods: The leaves of E. camaldulensis were collected, authenticated and extracted with methanol. The extract (100, 200, and 400 mg/kg), normal saline (negative control), and aspirin (positive control) were administered orally to egg-induced paw oedema rats of five groups of five rats each. The extract was partitioned, and each of the solvent fractions was assayed for its anti-inflammatory activity. The results obtained were subjected to one-way analysis of variance (ANOVA) followed by Bonferroni post hoc tests, and p < 0.05 was considered significant. Also, the most active fraction was subjected to gas chromatography-mass spectrometry (GC-MS) analysis.
Results: The extract at 100 mg/kg demonstrated the best anti-inflammatory effect at 29%, while the n-hexane (N-HEX) fraction gave the highest inflammatory inhibition at 43%. α-Phellandrene, o-cymene, n-hexadecanoic acid, and beta-sitosterol were identified as the most abundant compounds in the N-HEX fraction.
Conclusions: The study concluded that the methanol extract of E. camaldulensis possesses good anti-inflammatory properties, and its non-polar fraction was responsible for the observed activity. Bioassay-guided purification of anti-inflammatory constituents of the N-HEX fraction is recommended for future studies.
inflammation / Eucalyptus camaldulensis / extract / GC-MS
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
/
| 〈 |
|
〉 |